Physician profile
Andrew Corbin
NPI 1871078501
$1,720.74
in general payments reported to CMS, 2019-2025
17 companies · $573 in 2025
The $573 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $319 · 2022: $13.20 · 2023: $219 · 2024: $596 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,388.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $248.16 | 2021-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $209.62 | 2024-2025 | Cobenfy |
| Abbvie INC. | $199.49 | 2023-2025 | |
| Alkermes, INC. | $197.25 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $195.39 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $152.74 | 2021-2025 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $120.86 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $87.04 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $59.28 | 2023-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $55.26 | 2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Collegium Pharmaceutical, INC. | $42.15 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $38.81 | 2023-2024 | Auvelity, Sunosi |
| Ironshore Pharmaceuticals INC. | $32.54 | 2024 | |
| Harmony Biosciences LLC | $27.88 | 2025 | |
| Neos Therapeutics, LP | $21.40 | 2024 | Adzenys Xr-Odt |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $19.67 | 2024 | Perseris |
| Sunovion Pharmaceuticals INC. | $13.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Corbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.